Efficacy and safety of Aviandr in patients with anxiety disorders after coronavirus infection (COVID-19): interim results of a multicenter observational post-registration study
Authors:   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Kinkulkina M. A. , Danilov A. B. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Volel B. A. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Morozov E. N. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Rozhkov D. O. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Ivaschenko A. V. ,   ChemDiv Inc., San Diego USA, Ivaschenko A. A. ,   ChemRar Pharma, Moscow, Russian Federation, Ivanets N. N. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Tikhonova Yu. G. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Izyumina T. A. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Belyaeva P. A. ,   Psychotherapy Center «Podderzhka», Stavropol, Russian Federation, Dedkova V. A. ,   «Eco-Safety» R&D Center, Saint Petersburg, Russian Federation, Izmailova O. V. ,   Samara State Medical University, Samara, Russian Federation, Golovkina D. A. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Goncharova E. M. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Ivaschenko A. A. ,   Lomonosov Moscow State University, Moscow, Russian Federation, Morozov A. E. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow, Tarasov V. V. ,   Sechenov First Moscow State Medical University (Sechenov University), Moscow
Published: February 2025

Prevalence of anxiety disorders has increased in last decades, specifically in COVID-19 pandemic. Despite the frequency and burden of post-COVID anxiety disorders, there are still no recommendations for the treatment of these conditions. The article presents the interim results of a post-registration multicenter observational study of the efficacy
and safety of a new original drug Aviandr in the treatment of anxiety developing after COVID-19. The study included 170 patients over 18 years of age treated by Aviandr for 6 weeks at a dose of 20 mg 2 times a day. All patients completed 6 weeks of treatment and 2 weeks of follow-up. The decrease in the average total score of the Hamilton Rating Scale for Anxiety (SIGH-A) was 77.13 % of the baseline values. Most patients experienced clinical improvement; 72.35 % patients have reached remission by week 6 of therapy. The drug was equally effective in different age groups (≤/> 65 years). It is important to note that Aviandr was effective in relieving both mental and somatic anxiety, measured with
SIGH-A scale — the reduction in average scores was 75.13 % and 79.12 %, respectively. The study drug showed a good safety profile. Adverse events were observed in 5.88 % of patients; 85.7 % of AEs were mild, only 14.3 % were moderate. Thus, Aviandr showed good efficacy in the treatment of anxiety disorders after COVID-19. The absence of withdrawal syndrome, drug dependence, a high safety profile, including in elderly patients, make Aviandr a good choice for use in clinical practice.